Read by QxMD icon Read


Erika Scott, Jafar S Hasbullah, Colin Jd Ross, Bruce C Carleton
No abstract text is available yet for this article.
September 14, 2018: Pharmacogenomics
Theresa R Tonozzi, Glenn D Braunstein, Anja Kammesheidt, Chris Curran, Shahrokh Golshan, John Kelsoe
AIM: To compare pharmacogenetic test predictions with self-reported treatment experience and side effect tolerability among patients with depression taking psychotherapeutic medications. METHODS: Subjects completed a survey recalling medication effectiveness and side effects and then underwent pharmacogenetic testing. RESULTS: Our 15 gene pharmacogenetic panel predicted efficacy (p < 0.001) but did not predict side effect tolerability (p = 0...
September 12, 2018: Pharmacogenomics
Hedy Maagdenberg, Marc B Bierings, C Heleen van Ommen, Felix Jm van der Meer, Inge M Appel, Rienk Yj Tamminga, Saskia le Cessie, Jesse J Swen, Tahar van der Straaten, Anthonius de Boer, Anke H Maitland-van der Zee
AIM: To study the effects of clinical and genetic factors on the phenprocoumon dose requirement in pediatric patients and to develop a dosing algorithm. METHODS: Pediatric patients who used phenprocoumon were invited to participate in a retrospective follow-up study. Clinical information and genotypes of genetic variations in CYP2C9, VKORC1, CYP4F2, CYP2C18 and CYP3A4 were collected and tested with linear regression for association with phenprocoumon dose requirement...
September 12, 2018: Pharmacogenomics
Jacob S Young, Michael D Prados, Nicholas Butowski
Glioblastoma has been shown to have many different genetic mutations found both within and between tumor samples. Molecular testing and genomic sequencing has helped to classify diagnoses and clarify difficult to interpret histopathological specimens. Genomic information also plays a critical role in prognostication for patients, with IDH mutations and MGMT methylation having significant impact of the response to chemotherapy and overall survival of patients. Unfortunately, personalized medicine and targeted therapy against specific mutations have not been shown to improve patient outcomes...
September 11, 2018: Pharmacogenomics
Sarah Sim, Jonas Bergh, Mats Hellström, Thomas Hatschek, Hanjing Xie
AIM: This study aimed to investigate the effect of CYP3A4 and CYP3A5 genotypes on clinical outcomes of docetaxel treatment. PATIENTS & METHODS: In the PROMIX trial, 150 breast cancer patients received docetaxel preoperatively. CYP3A4 and CYP3A5 genotype combinations were transformed into total CYP 3A phenotypes. RESULTS: Seven patients were characterized as poor metabolizer (PM), 22 patients as extensive metabolizer and 121 patients as intermediate metabolizer...
September 10, 2018: Pharmacogenomics
Jasmine A Luzum, Jason C Cheung
Current guideline recommendations for pharmacogenetic testing for clopidogrel by the American Heart Association/American College of Cardiology (AHA/ACC) contradict the Clinical Pharmacogenetics Implementation Consortium and the US FDA. The AHA/ACC recommends against routine pharmacogenetic testing for clopidogrel because no randomized controlled trials have demonstrated that testing improves patients' outcomes. However the AHA/ACC and the National Comprehensive Cancer Network (NCCN) recommend other pharmacogenetic tests in the absence of randomized controlled trials evidence...
September 10, 2018: Pharmacogenomics
Rachid Abaji, Francesco Ceppi, Swati Patel, Vincent Gagné, Chang J Xu, Jean-François Spinella, Antonella Colombini, Rosanna Parasole, Barbara Buldini, Giuseppe Basso, Valentino Conter, Giovanni Cazzaniga, Jean-Marie Leclerc, Caroline Laverdière, Daniel Sinnett, Maja Krajinovic
AIM: To identify genetic markers associated with vincristine-induced peripheral neuropathy (VIPN) in childhood acute lymphoblastic leukemia. PATIENTS & METHODS: Whole-exome sequencing data were combined with exome-wide association study to identify predicted-functional germline variants associated with high-grade VIPN. Genotyping was then performed for top-ranked signals (n = 237), followed by validation in independent replication group (n = 405). RESULTS: Minor alleles of rs2781377/SYNE2 (p = 0...
September 7, 2018: Pharmacogenomics
Shirley Siang Ning Tan, Keng Tat Koh, Lee Len Tiong, Tiong Kiam Ong, Alan Yean Yip Fong
AIM: Recurrent thrombotic events still occur despite dual antiplatelet therapy in patient's post percutaneous coronary intervention (PCI) could be attributed to high on-treatment platelet reactivity. METHODS: A 44-year-old male, who had staged PCI to left anterior descending (LAD) 2 weeks after an anterior MI, with a drug-coated stent was readmitted with new anterior STEMI 35 days later. Coronary angiogram revealed mid-stent thrombus in situ. He had further uncomplicated PCI...
September 7, 2018: Pharmacogenomics
Corine Ekhart, Maja Matic, Agnes Kant, Laure Elens, Eugène van Puijenbroek, Ron van Schaik
Letter in reply to: Eikelenboom-Schieveld SJM, Fogleman JC. Letter to the Editor. Pharmcogenomics 19(14), doi:10.2217/pgs-2018-0203 (2018) (Epub ahead of print) [ 1 ], regarding: Ekhart, Matic M, Kant A, van Puijenbroek E, van Schaik R. CYP450 genotype and aggressive behavior on selective serotonin reuptake inhibitors. Phamacogenomics 18(7), 613-620 (2017) [ 2 ].
August 31, 2018: Pharmacogenomics
Selma Jm Eikelenboom-Schieveld, James C Fogleman
Letter regarding: Ekhart C, Matic M, Kant A, van Puijenbroek E, Schaik RV. CYP450 genotype and aggressive behavior on selective serotonin reuptake inhibitors. Pharmacogenomics 18(7), 613-620 (2017) [ 1 ].
August 31, 2018: Pharmacogenomics
Rong Liu, Rong Hu, Wei Zhang, Hong-Hao Zhou
AIM: We aimed to develop a long noncoding RNA (lncRNA) expression signature that can predict response to tamoxifen. MATERIALS & METHODS: LncRNA expression profiling was mined in two cohorts from Gene Expression Omnibus (GSE6532, GSE9195, n = 412). RESULTS: A set of lncRNAs (LINC01191, RP4-639F20.1 and CTC-429P9.3) associated with distant metastasis-free survival was established. Estrogen receptor-positive breast cancer patients in the training series could be classified into high- and low-risk groups with significantly different distant metastasis-free survival values based on this signature (hazard ratio [HR]: 5...
July 9, 2018: Pharmacogenomics
Shangchen Xie, Wenjuan Ma, Minxue Shen, Qulian Guo, E Wang, Changsheng Huang, Yueling Wang, Xiang Chen, Zhaoqian Liu, Wei Zhang, Howard L McLeod, Yijing He
AIM: Delayed recovery from general anesthesia is a well-known complication that requires predictive tools and approaches. This study aimed to determine significant factors associated with postanesthesia recovery and to develop an algorithm for estimating recovery time from general anesthesia. MATERIALS & METHODS: The genotypes of patients were determined by SNaPshot or ARMS-qPCR. The algorithm was developed via machine-learning and tested by the worm plot. RESULTS: Results showed that OPRM1 rs1799971 (p = 0...
September 1, 2018: Pharmacogenomics
Gideon Koren, Asher Ornoy
Depression occurs during pregnancy in 3.9-12.8% of the women. The different serotonin reuptake inhibitors (SRIs) are metabolized in the liver by CYP450 enzymes. CYP2D6 metabolizes paroxetine, fluoxetine, duloxetine and venlafaxine, while CYP2C19 deactivates citalopram and escitalopram. Polymorphisms in these enzymes change the metabolic clearance and levels of these drugs. Higher metabolism of most SRIs in late pregnancy results in lower maternal levels, which could result in decreased efficacy. Very few studies have addressed the potential interaction between pregnancy-induced increase in 2D6 metabolism and specific genotypes of the women, suggesting that ultra-rapid and extensive metabolizers exhibit lower serum concentrations than the other slower genotypes...
September 1, 2018: Pharmacogenomics
Abdelrahman H Elsayed, Xueyuan Cao, Kristine R Crews, Varsha Gandhi, William Plunkett, Jeffrey E Rubnitz, Raul C Ribeiro, Stanley B Pounds, Jatinder K Lamba
AIM: Cytarabine (Ara-C), a mainstay of acute myeloid leukemia (AML) treatment, is a prodrug requiring activation to ara-CTP for its antileukemic activity. Aim of this study was to evaluate impact of genetic variants in the key genes involved in ara-C metabolism on the leukemic cell intracellular levels of ara-CTP. METHOD:  We investigated SNPs in 14 ara-C metabolic-pathway genes, for association with intracellular ara-CTP levels, in leukemic cells obtained post-initiation of cytarabine infusion in pediatric AML patients (n = 68)...
September 1, 2018: Pharmacogenomics
Barbara M Parker, Sara L Rogers, Anastasios Lymperopoulos
No abstract text is available yet for this article.
September 1, 2018: Pharmacogenomics
Magnus Ingelman-Sundberg, Volker M Lauschke
Recent phenotypically and functionally relevant human hepatic in vitro systems combine the ability to preserve interindividual molecular differences between patients' livers in culture with the accessibility and high-throughput compatibility of in vitro assays. These features facilitate studies of specific genetic polymorphisms by using cells from donors with defined variants of interest or by selective gene knock-down experiments. Furthermore, these models constitute promising tools to evaluate drug-drug interactions as well as the effects of liver diseases on drug pharmacokinetics in co-cultures of hepatocytes and non-parenchymal cells...
September 1, 2018: Pharmacogenomics
Na Liu, Guihua Yang, Mei Hu, Yuyu Cai, Zhiying Hu, Chundi Jia, Man Zhang
AIM: The clinical benefits of lipid-lowering therapy with statins are widely recognized. However, the lipid-lowering efficacy of statins shows significant differences between individuals. ABCC2 has been demonstrated to contribute to the transmembrane transport of the substrate compounds. The ABCC2 SNPs may be important factors that affect individual differences in clinical drug response. The aim of this study was to evaluate the association of rs717620 of ABCC2 with treatment response to simvastatin in a Chinese Han population...
September 1, 2018: Pharmacogenomics
María Del Carmen Plaza-Serón, Elena García-Martín, Jose Augusto Agúndez, Pedro Ayuso
Nonsteroidal anti-inflammatory drugs are the medications most frequently involved in hypersensitivity reactions to drugs. These can be induced by specific immunological and nonimmunological mechanisms, being the latter the most frequent. The nonimmunological mechanism is related to an imbalance of inflammatory mediators, which is aggravated by the cyclooxygenase inhibition. Genetic studies suggest that multiples genes and additional mechanisms might be involved. The proposals of this review is summarize the contribution of variations in genes involved in the arachidonic acid, inflammatory and immune pathways as well as the recent genome-wide association studies findings related to cross-intolerant nonsteroidal anti-inflammatory drugs hypersensitivity reactions...
August 1, 2018: Pharmacogenomics
Ellie H Jhun, Nilanjana Sadhu, Yingwei Yao, Ying He, Robert E Molokie, Diana J Wilkie, Zaijie Jim Wang
AIM: Pain in sickle cell disease patients is heterogeneous and genetic polymorphisms may predispose an individual to varied vulnerability to painful events. We studied the association of SNPs in the glucocorticoid receptor gene (NR3C1) with pain in sickle cell disease. METHOD: Acute pain was scored as the number of utilizations due to crisis pain in a 12-month period. Chronic pain was calculated as the Composite Pain Index score. RESULTS & CONCLUSION: rs33389 T allele (IRR = 1...
August 1, 2018: Pharmacogenomics
Alessandra Raimondi, Federico Nichetti, Giorgia Peverelli, Maria Di Bartolomeo, Filippo De Braud, Filippo Pietrantonio
Gastric cancer is a highly heterogeneous disease, displaying a complex genomic landscape and an unfavorable outcome with standard therapies. Based on distinctive genomic alterations, novel targeted agents have been developed with the aim of personalizing treatments and improving patient outcome. However, a subgroup of patients is primarily treatment-resistant, and even in the initially sensitive population, secondary resistance emerges, thus limiting therapeutic benefit. In this review, we summarize the clinical data about standard targeted agents in gastric cancer, specifically anti-HER2 treatments and antivascular therapies...
August 1, 2018: Pharmacogenomics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"